Grid Dynamics Helps SmartRay Create an AI Robotic Inspection Platform in Collaboration with Wandelbots
17.7.2025 15:15:00 CEST | Business Wire | Press Release
Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (Grid Dynamics), a leading provider of technology consulting, platform and product engineering, AI, and digital engagement services, today announced the successful launch of SmartRay’s new software platform for robotic weld inspection. Drawing on its deep expertise in robotic control, advanced optimization, and AI engineering, Grid Dynamics helped transform robotic programming workflows at SmartRay—a global leader in high-end weld seam inspection—enabling greater automation, faster time-to-market, and significant cost reductions.
Innovating weld inspection by combining specialized 3D sensors with advanced processing algorithms is central to SmartRay’s long-term strategy. Grid Dynamics extended SmartRay’s software ecosystem with AI applications for workpiece feasibility checks and tool path generation, reducing the time required for initial analysis and path creation from days to minutes. The solution was built on the Wandelbots NOVA platform in close collaboration with the Wandelbots engineering team, delivering a seamless workflow—from feasibility checks and tool path creation to robot trajectory execution across a broad range of manipulators, thanks to NOVA’s cross-platform hardware abstraction layer.
"Advancements in foundational embodied AI models can dramatically expand the applicability of robotics, creating significant demand for the associated hardware and software ecosystem—from robot programming platforms to observability tools to model and dataset management solutions," said Ilya Katsov, CTO, Americas at Grid Dynamics. "Our work with SmartRay and Wandelbots marks a key milestone in the journey toward next-generation robotics, allowing us to test and apply cutting-edge methods and technologies."
"We provide our customers with best-in-class turnkey weld inspection solutions, objective 100% quality control and data-driven process optimization," said Bernd Lorösch, VP Business Unit JOSY at SmartRay. "With Grid Dynamics’ expertise, we can now offer next-generation robotic intelligence that dramatically simplifies the integration and operation of our solutions by automating critical tasks like feasibility analysis and tool path optimization."
"Wandelbots NOVA is transforming how companies approach robotic programming and operations in the age of AI," said Stephan Hotz, Chief Product & Technology Officer at Wandelbots. "By providing our platform as a basis enriched with domain-specific AI components developed by Grid Dynamics, we empower businesses to deploy robotic solutions faster and achieve meaningful gains in efficiency and cost savings. These collaborations lay the foundation for transforming our industries with physical AI."
This robotics AI initiative expands Grid Dynamics’ ability to deliver transformative solutions to clients in manufacturing, logistics, and high-tech industries. To learn more about the AI Robotic Inspection Platform, read the case study.
About Grid Dynamics
Grid Dynamics (Nasdaq: GDYN) is a leading provider of technology consulting, platform and product engineering, AI, and digital engagement services. Fusing technical vision with business acumen, we solve the most pressing technical challenges and enable positive business outcomes for enterprise companies undergoing business transformation. Founded in 2006, Grid Dynamics is headquartered in Silicon Valley with offices across the Americas, Europe, and India. Follow us on LinkedIn.
About SmartRay
SmartRay specialises in 3D sensors for measuring tasks, quality inspection and complete solutions for weld seam inspection. With the turnkey JOSY weld inspection solution, manufacturing companies can improve their product quality, optimize their automation processes and reduce production costs. By focusing 100% on 3D technology, SmartRay has built a comprehensive portfolio that quickly and reliably solves a wide range of 3D applications even beyond weld inspection. For more details, visit www.smartray.com.
About Wandelbots
Wandelbots empowers enterprises to transform industrial robotics into software-defined, continuously optimizing systems. With its unified platform – including the Wandelbots Cloud Platform, the Developer Portal and the Wandelbots NOVA Operating System – manufacturing companies automate faster, optimize smarter, and scale global operations with confidence. For more information, visit www.wandelbots.com.
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that are not historical facts, and involve risks and uncertainties that could cause actual results of Grid Dynamics to differ materially from those expected and projected. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “may,” “will,” “potential,” “projects,” “predicts,” “continue,” or “should,” or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include, without limitation, quotations and statements regarding the expected benefits of our capabilities and our company’s future growth including with customers, and the AI Robotics Inspection Platform with SmartRay.
These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside Grid Dynamics’ control and are difficult to predict. Factors that may cause such differences include, but are not limited to our ability to achieve its expected benefits, as well as any factors limiting our capabilities, and the benefits of our services and products.
Grid Dynamics cautions that the foregoing list of factors is not exclusive. Grid Dynamics cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Grid Dynamics does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based. Further information about factors that could materially affect Grid Dynamics, including its results of operations and financial condition, is set forth under the “Risk Factors” section of Grid Dynamics’ annual report on Form 10-K filed February 27, 2025, and in other periodic filings Grid Dynamics makes with the SEC.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250717650305/en/
Contacts
Media Contacts:
Grid Dynamics
Cary Savas
+1 (650) 523 5000
csavas@griddynamics.com
Wandelbots
Carrie Eyerly
+49 351 86264000
contact@wandelbots.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom